SLT (CognivAiD™) Improves Memory and Cognition in Individuals With Mild Cognitive Impairment: Clinical Trial Results
Investigator-initiated clinical trial of SLT (CognivAiD™) for mild cognitive impairment, led by Western Sydney University’s NICM Health Research Institute.
- Investigator-initiated clinical trial of SLT (CognivAiD™) for mild cognitive impairment, led by Western Sydney University’s NICM Health Research Institute.
- Trial results reported that CognivAiD™ significantly improved key cognitive domains of episodic memory and executive function, and was well-tolerated.
- SINGAPORE, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Moleac, a biopharmaceutical company pioneering innovative therapeutics in neurology, announced promising results from an investigator-led clinical trial conducted on SLT (CognivAiD™) in mild cognitive impairment (MCI).
- Individuals with MCI are at increased risk of developing dementia later on.